News & Updates

Upadacitinib promising in first 52 weeks of SELECT-GCA trial

01 Aug 2024 by

The JAK inhibitor upadacitinib brought sustained remission in the first 52 weeks of the phase III SELECT-GCA study of patients with new-onset or relapsing giant cell arteritis (GCA).

Upadacitinib promising in first 52 weeks of SELECT-GCA trial

01 Aug 2024

First-line abatacept improves disease remission in RA

01 Aug 2024

The use of abatacept as a first-line biologic treatment appears to result in greater remission in rheumatoid arthritis (RA), especially if the drug is used continuously, as shown in a real-world study from Taiwan.

First-line abatacept improves disease remission in RA

01 Aug 2024

Dietary manganese helps lower uric acid levels in Chinese adults

23 Jul 2024

Eating foods high in manganese appears to confer protection against hyperuricaemia in Chinese adults, as shown in a study.

Dietary manganese helps lower uric acid levels in Chinese adults

23 Jul 2024

Bimekizumab may protect against uveitis in axial spondyloarthritis

22 Jul 2024

In the treatment of patients with axial spondyloarthritis (axSpA), the dual IL-17A/F inhibitor bimekizumab appears to lower the risk of uveitis, according to a study.

Bimekizumab may protect against uveitis in axial spondyloarthritis

22 Jul 2024

Benralizumab facilitates complete withdrawal of OGCs more than mepolizumab in EGPA

22 Jul 2024 by

Benralizumab offers more sustained and earlier elimination of oral GCs vs mepolizumab in patients with relapsing or refractory EGPA, suggests a post hoc analysis of the MANDARA study presented at EULAR 2024

Benralizumab facilitates complete withdrawal of OGCs more than mepolizumab in EGPA

22 Jul 2024

JAK inhibitors for autoimmune disease may confer protection against AMD

20 Jul 2024 by

The use of Janus kinase (JAK) inhibitors in the treatment of major autoimmune diseases appears to reduce the risk of age-related macular degeneration (AMD) for people above 40 years of age, according to a study.

JAK inhibitors for autoimmune disease may confer protection against AMD

20 Jul 2024

Nearly 9 in 10 children with juvenile PsA or ERA achieve ACR30 with ixekizumab

19 Jul 2024 by

Treatment with ixekizumab resulted in almost 90 percent of children with active juvenile psoriatic arthritis (JPsA) or enthesitis-related arthritis (ERA) achieving an ACR30* response by week 16, according to the ongoing COSPIRIT-JIA trial presented at EULAR 2024.

Nearly 9 in 10 children with juvenile PsA or ERA achieve ACR30 with ixekizumab

19 Jul 2024

Novel IL-17A inhibitor helps dial down psoriatic arthritis disease activity

17 Jul 2024 by

Potent and selective inhibition of IL-17A by izokibep produced a rapid improvement in disease activity across multiple psoriatic arthritis (PsA) domains, according to preliminary data from a phase IIb/III trial.

Novel IL-17A inhibitor helps dial down psoriatic arthritis disease activity

17 Jul 2024

Upadacitinib proves long-term efficacy in RA

17 Jul 2024 by

Upadacitinib remains effective through 5 years in patients with rheumatoid arthritis (RA) who have inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), with no new safety signals, as shown by the results of the phase III long-term extension (LTE) of SELECT-NEXT.

Upadacitinib proves long-term efficacy in RA

17 Jul 2024

Targeting IL-5 in hypereosinophilic diseases: From bench to bedside

17 Jul 2024 by

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare eosinophilic autoimmune disease that affects multiple organs. The lack of disease awareness and heterogeneous nature of clinical manifestations have made diagnosis and management of EGPA challenging. At Advances in Medicine (AIM) 2024, Professor Hiromichi Tamaki, a rheumatologist from St. Luke’s International Hospital in Japan, discussed how EGPA is diagnosed, presented real-world evidence on mepolizumab (an anti–interleukin [IL]-5 therapy) in EGPA and illustrated mepolizumab’s clinical benefits through several patient cases.

Targeting IL-5 in hypereosinophilic diseases: From bench to bedside

17 Jul 2024

News & Updates

Filter by Specialty:

Specialty:

Upadacitinib promising in first 52 weeks of SELECT-GCA trial

Upadacitinib promising in first 52 weeks of SELECT-GCA trial

First-line abatacept improves disease remission in RA

First-line abatacept improves disease remission in RA

Dietary manganese helps lower uric acid levels in Chinese adults

Dietary manganese helps lower uric acid levels in Chinese adults

Bimekizumab may protect against uveitis in axial spondyloarthritis

Bimekizumab may protect against uveitis in axial spondyloarthritis

Benralizumab facilitates complete withdrawal of OGCs more than mepolizumab in EGPA

Benralizumab facilitates complete withdrawal of OGCs more than mepolizumab in EGPA

JAK inhibitors for autoimmune disease may confer protection against AMD

JAK inhibitors for autoimmune disease may confer protection against AMD

Nearly 9 in 10 children with juvenile PsA or ERA achieve ACR30 with ixekizumab

Nearly 9 in 10 children with juvenile PsA or ERA achieve ACR30 with ixekizumab

Novel IL-17A inhibitor helps dial down psoriatic arthritis disease activity

Novel IL-17A inhibitor helps dial down psoriatic arthritis disease activity

Upadacitinib proves long-term efficacy in RA

Upadacitinib proves long-term efficacy in RA

Targeting IL-5 in hypereosinophilic diseases: From bench to bedside

Targeting IL-5 in hypereosinophilic diseases: From bench to bedside